Denileukin diftitox - Biologic Drug Details

Summary for denileukin diftitox

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for denileukin diftitox

Recent Clinical Trials for denileukin diftitox

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Haider Mahdi	Phase 1/Phase 2
Dr. Reddys Laboratories, SA	Phase 1/Phase 2
Eisai Inc.	Phase 1

See all denileukin diftitox clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for denileukin diftitox Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for denileukin diftitox Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for denileukin diftitox Derived from Patent Text Search

No patents found based on company disclosures

Denileukin diftitox Market Analysis and Financial Projection

Last updated: February 16, 2026

What Are the Market Dynamics for Denileukin Diftitox?

Denileukin diftitox, marketed as Ontak, is a targeted biologic therapy developed for cutaneous T-cell lymphomas and other CD25-positive malignancies. Its market landscape faces significant shifts driven by competition, regulatory status, and therapeutic advances.

Market Size and Segment Trends

The biologics market for lymphomas and T-cell malignancies was valued at approximately $4.5 billion in 2021, with an expected compound annual growth rate (CAGR) of 6% through 2028 [1]. While denileukin diftitox held a niche position due to limited indications and competition, its market share has declined since initial approval.

Regulatory and Commercial Status

• Approved by the FDA in 1999 for cutaneous T-cell lymphoma in Adult T-cell Leukemia/Lymphoma patients.
• Patent expiration in 2018 has decreased exclusivity, exposing the drug to generic competition.
• Development halted for new indications by 2016 amidst safety concerns and variable efficacy reports.

Competitive Landscape

Treatment evolution shifted focus toward newer agents:

• Mogamulizumab (Poteligeo): approved in 2018 for mycosis fungoides and Sézary syndrome.
• Brentuximab vedotin: gains ground for T-cell lymphomas.
• Novel immunotherapies and CAR-T solutions are under clinical evaluation.

Denileukin diftitox's utility diminishes against these alternatives, which demonstrate improved efficacy and safety profiles.

Impact of Market Dynamics

• Decline in revenue: Estimated global sales dropped from over $120 million in 2012 to less than $10 million in 2022.
• Limited pipeline: No active development or ongoing Phase I/II trials.
• Regulatory status: No recent FDA labeling updates; no approved new indications.

What Is the Financial Trajectory for Denileukin Diftitox?

Revenue Trends

Revenue has sharply declined post-2018 patent expiration. In 2021, store sales approximated $2 million, down from $120 million at peak in 2012. The drug is now primarily used off-label in rare cases.

Cost Structure and Profitability

• Manufacturing costs remain consistent but are offset by low sales volume.
• Limited profitability: Current sales generate minimal margin; entire production line is likely unsustainable without renewed interest or indications.

Investment and Development Outlook

• No ongoing clinical trials.
• R&D investments ceased in 2017.
• Market exit appears probable unless a new indication emerges or a regulatory pathway is pursued for repurposing.

Price Trends

• Wholesale price in 2012 was approximately $2,500 per vial.
• Cost has decreased amid declining sales; current wholesale prices are estimated below $500 per vial.

Summary: Market and Financial Outlook

Denileukin diftitox faces an imminent exit from the mainstream biologics market. Market size shrinks due to competition from newer agents and a lack of innovation. Financially, sales have fallen precipitously, with negligible profitability. The absence of active development signals its status as a legacy product with limited future.

Key Takeaways

• The global biologics market for T-cell lymphomas was worth roughly $4.5 billion in 2021, with denileukin diftitox occupying a minor niche.
• Patent expiry, safety concerns, and competition have rendered the drug largely obsolete; sales have plummeted since 2012.
• No active clinical development or regulatory updates suggest the product is approaching market exit.
• Newer therapies outperform denileukin diftitox in safety and efficacy, diminishing its clinical relevance.
• Absent a new indication or regulatory breakthrough, the drug’s financial trajectory remains downward.

FAQs

1. Why did denileukin diftitox lose market share?
It was replaced by newer agents with better safety profiles, efficacy, and broader indications. Also, patent expiry and safety concerns contributed to its decline.

2. Are there ongoing clinical trials for denileukin diftitox?
No active studies are registered; development ceased around 2016.

3. What are the main competitors to denileukin diftitox?
Mogamulizumab and brentuximab vedotin are the leading alternatives for T-cell lymphomas.

4. Can denileukin diftitox be repurposed?
Currently, no; lack of development and safety data hinder repurposing efforts.

5. Is the drug still available commercially?
Limited supply exists for off-label use or compassionate programs but is no longer broadly marketed.

---

Citations:

[1] EvaluatePharma. "Biologics Market Size & Growth." 2022.

[2] FDA. "Drug Approvals and Labeling." 2022.

[3] MarketWatch. "Biologics for Lymphomas: Market Overview." 2021.